Workflow
Perspective Therapeutics(CATX)
icon
Search documents
Perspective Therapeutics(CATX) - 2020 Q1 - Earnings Call Transcript
2019-11-12 23:47
IsoRay, Inc. (ISR) Q1 2020 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - Co-Principal Financial Officer Conference Call Participants Ed Woo - Ascendiant Capital Arthur He - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the IsoRay First Quarter Fiscal 2020 Call. All lines have been placed in a listen-only mode and the floor will be open for your questions and comments following the presentation. At this ti ...
Perspective Therapeutics(CATX) - 2019 Q4 - Annual Report
2019-09-27 21:13
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended June 30, 2019 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File No. 001-33407 Isoray, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |---------------- ...
Perspective Therapeutics(CATX) - 2019 Q4 - Earnings Call Transcript
2019-09-25 02:15
IsoRay, Inc. (ISR) Q4 2019 Results Earnings Conference Call September 24, 2019 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - Co-Principal Financial Officer Conference Call Participants Jason Kolbert - Dawson James Ed Woo - Ascendiant Capital Operator Good day, ladies and gentlemen, and welcome to the IsoRay Fourth Quarter Fiscal 2019 Conference Call. All lines have been placed in a listen-only mode and the floor will be open for your questions and comments following the p ...
Perspective Therapeutics(CATX) - 2019 Q3 - Quarterly Report
2019-05-10 20:42
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-33407 Isoray, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1458152 (State ...
Perspective Therapeutics(CATX) - 2019 Q3 - Earnings Call Transcript
2019-05-09 22:03
Start Time: 16:30 January 1, 0000 4:51 PM ET IsoRay, Inc. (ISR) Q3 2019 Earnings Conference Call May 09, 2019, 16:30 PM ET Company Participants Lori Woods - CEO Jonathan Hunt - CFO Mark Levin - IR Conference Call Participants Edward Woo - Ascendant Capital Operator Good day, ladies and gentlemen, and welcome to the IsoRay Third Quarter Fiscal 2019 Call. All lines have been placed in a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructio ...
Perspective Therapeutics(CATX) - 2019 Q2 - Earnings Call Transcript
2019-02-13 00:08
IsoRay, Inc. (ISR) Q2 2019 Earnings Conference Call February 12, 2019 4:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Jonathan Hunt - CFO Conference Call Participants RK Swayampakula - H.C. Wainwright Operator Good day ladies and gentlemen and welcome to the IsoRay Second Quarter 2019 Call. All lines have been placed on a listen-only mode and the floor will be open for your questions and comments following the presentation. [Operator Instructions]. At this time, it is my pleasure to turn th ...
Perspective Therapeutics(CATX) - 2019 Q2 - Quarterly Report
2019-02-12 22:39
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-33407 | --- | --- | |---------------------------------------------------------------------------- ...